3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
28
Genitourinary
2
Breast
2
Thoracic
1
Other solid neoplasm
1
Head & Neck
1
Gastrointestinal
1
Conditions
Nasopharyngeal Carcinoma
71
Nasopharyngeal Neoplasms
25
Head and Neck Neoplasms
25
Squamous Cell Carcinoma of Head and Neck
18
Neoplasm Metastasis
14
Carcinoma, Non-Small-Cell Lung
11
Recurrence
9
Salivary Gland Neoplasms
7
Ovarian Neoplasms
7
Stomach Neoplasms
6
Pancreatic Neoplasms
6
Small Cell Lung Carcinoma
5
Prostatic Neoplasms
5
Neoplasms
5
Melanoma
5
Colorectal Neoplasms
5
Breast Neoplasms
5
Triple Negative Breast Neoplasms
4
Sarcoma
4
Lung Neoplasms
4
Esophageal Neoplasms
4
Urinary Bladder Neoplasms
3
Thyroid Neoplasms
3
Laryngeal Diseases
3
Epstein-Barr Virus Infections
3
Colonic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Osteosarcoma
2
Oropharyngeal Neoplasms
2
Mouth Neoplasms
2
Interventions
pembrolizumab
30
Nivolumab
10
Cyclophosphamide
9
fludarabine
7
atezolizumab
7
aldesleukin
5
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Ipilimumab
5
Carboplatin
5
Biopsy
5
cemiplimab
4
Trastuzumab
4
Interleukin-2
4
Docetaxel
4
Cisplatin
4
spartalizumab
3
durvalumab
3
Specimen Handling
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Fulvestrant
3
Fluorouracil
3
tisotumab vedotin
2
tislelizumab
2
palbociclib
2
fludarabine phosphate
2
entinostat
2
avelumab
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Gemcitabine
×
Head & Neck
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled